Bayer presents new data across oncology portfolio at the 2023 ASCO Annual Meeting
25
Might perchance possibly also
2023
|
13:59 PM
Europe/Amsterdam
No longer intended for U.S. and UK Media
Summary
Bayer continues to level of curiosity on advancing prostate most cancers care from early to metastatic stage with darolutamide recordsdata in non-metastatic castration-resistant prostate most cancers (nmCRPC) and metastatic hormone-tender prostate most cancers (mHSPC), and radium-223 dichloride recordsdata in metastatic castration-resistant prostate most cancers (mCRPC) / Confirming Bayer’s funding in Precision Oncology, larotrectinib recordsdata introduced at ASCO expose prolonged-term efficacy and security in patients with tropomyosin receptor kinase (TRK) fusion lung and thyroid most cancers, to boot to recordsdata from investigator-initiated research in pediatric patients with newly diagnosed infantile fibrosarcoma (IFS)
